{"id":12665,"date":"2023-04-26T13:54:00","date_gmt":"2023-04-26T11:54:00","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12665"},"modified":"2026-03-03T10:45:10","modified_gmt":"2026-03-03T09:45:10","slug":"medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/","title":{"rendered":"Communiqu\u00e9 de presse: <strong>R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse<\/strong>"},"content":{"rendered":"\n<p class=\"is-style-paragraph-lead-text\"><strong>En tant qu\u2019association de l\u2019industrie pharmaceutique pratiquant la recherche en Suisse, Interpharma voit dans la r\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutique \u00e0 la fois des chances et des risques. De nombreux points ne sont pas encore clairs et demanderont un examen approfondi. La strat\u00e9gie de l\u2019UE vise \u00e0 renforcer la coop\u00e9ration et \u00e0 harmoniser les normes sur le march\u00e9 du m\u00e9dicament au sein de l\u2019Union, ce qui pourrait avoir des cons\u00e9quences pour la Suisse en tant que pays ext\u00e9rieur \u00e0 l\u2019UE. Le risque est que de nouveaux obstacles retardent l\u2019acc\u00e8s aux m\u00e9dicaments innovants ici en Suisse, ou rendent plus difficile l\u2019exportation de m\u00e9dicaments suisses.<\/strong><\/p>\n\n\n\n<p>L\u2019UE s\u2019efforce, par une vaste strat\u00e9gie, de conserver sa comp\u00e9titivit\u00e9 en tant que place pharmaceutique, d\u2019assurer un acc\u00e8s rapide et \u00e9quitable aux m\u00e9dicaments, de r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits et de renforcer la s\u00e9curit\u00e9 d\u2019approvisionnement. \u00c0 l\u2019heure actuelle, la Suisse ne dispose h\u00e9las pas d\u2019une telle strat\u00e9gie globale contenant des mesures concr\u00e8tes pour le moteur de l\u2019exportation de notre pays. Cela pourrait nous nuire en tant que place pharmaceutique. La Suisse serait donc bien avis\u00e9e d\u2019examiner soigneusement la r\u00e9vision de l\u2019UE et d\u2019introduire elle aussi les mesures applicables pour am\u00e9liorer l\u2019attractivit\u00e9 de la place suisse. Elle ne doit en revanche en aucun cas imiter les \u00e9l\u00e9ments susceptibles de porter atteinte \u00e0 la force d\u2019innovation du site. Bien au contraire, il serait habile qu\u2019elle se cr\u00e9e un avantage concurrentiel.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-impact-problematique-sur-les-relations-bilaterales\"><strong>Impact probl\u00e9matique sur les relations bilat\u00e9rales<\/strong><\/h2>\n\n\n\n<p>Un grand probl\u00e8me est l\u2019impact \u00e9ventuel sur les relations bilat\u00e9rales. Tant pour le contenu que sur le plan juridique, certaines parties de l\u2019accord entre la Conf\u00e9d\u00e9ration suisse et l\u2019Union europ\u00e9enne sur la reconnaissance mutuelle des \u00e9valuations de conformit\u00e9 (ARM) dans le domaine pharmaceutique s\u2019appuient sur les r\u00e8gles actuellement en vigueur. Lorsque la r\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE sur les produits pharmaceutiques entrera en vigueur, il faudra mettre \u00e0 jour ces parties de l\u2019ARM pour maintenir leur validit\u00e9 juridique. Mais comme les accords existants ne sont plus mis \u00e0 jour, cela peut s\u2019av\u00e9rer extr\u00eamement probl\u00e9matique pour la place de production suisse.<\/p>\n\n\n\n<p>Nous sommes \u00e9galement critiques vis-\u00e0-vis de l\u2019affaiblissement envisag\u00e9 de la propri\u00e9t\u00e9 intellectuelle. Le d\u00e9veloppement d\u2019un m\u00e9dicament est une affaire extr\u00eamement risqu\u00e9e, dure en moyenne une douzaine d\u2019ann\u00e9es et co\u00fbte plus de 2&nbsp;milliards de francs. Sans une forte protection de la propri\u00e9t\u00e9 intellectuelle, la disposition \u00e0 investir du capital-risque dans la recherche et le d\u00e9veloppement diminuera. Ce serait une mauvaise nouvelle pour la place de recherche continentale ainsi que pour les patient-e-s du monde entier.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Interpharma suit de pr\u00e8s l\u2019\u00e9volution<\/strong><\/h2>\n\n\n\n<p>Tant dans le cadre de sa participation active \u00e0 l\u2019organisation fa\u00eeti\u00e8re europ\u00e9enne EFPIA que pour ce qui est de l\u2019impact sur la Suisse, Interpharma va suivre de tr\u00e8s pr\u00e8s la r\u00e9vision et en analyser l\u2019impact en continu. Nous mettrons tout en \u0153uvre pour qu\u2019une \u00e9troite coop\u00e9ration et le dialogue avec tous les partenaires permettent \u00e0 l\u2019industrie pharmaceutique suisse de conserver sa comp\u00e9titivit\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En tant qu\u2019association de l\u2019industrie pharmaceutique pratiquant la recherche en Suisse, Interpharma voit dans la r\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutique \u00e0 la fois des chances et des risques. De nombreux points ne sont pas encore clairs et demanderont un examen approfondi. La strat\u00e9gie de l\u2019UE vise \u00e0 renforcer la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2828,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[120,122,131],"class_list":["post-12665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-innovation-fr","tag-communique-de-presse","tag-politique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse\" \/>\n<meta property=\"og:description\" content=\"En tant qu\u2019association de l\u2019industrie pharmaceutique pratiquant la recherche en Suisse, Interpharma voit dans la r\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutique \u00e0 la fois des chances et des risques. De nombreux points ne sont pas encore clairs et demanderont un examen approfondi. La strat\u00e9gie de l\u2019UE vise \u00e0 renforcer la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T11:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:45:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1731\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse\",\"datePublished\":\"2023-04-26T11:54:00+00:00\",\"dateModified\":\"2026-03-03T09:45:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\"},\"wordCount\":601,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg\",\"keywords\":[\"Innovation\",\"Communiqu\u00e9 de presse\",\"Politique\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\",\"name\":\"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg\",\"datePublished\":\"2023-04-26T11:54:00+00:00\",\"dateModified\":\"2026-03-03T09:45:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg\",\"width\":2560,\"height\":1731},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse","og_description":"En tant qu\u2019association de l\u2019industrie pharmaceutique pratiquant la recherche en Suisse, Interpharma voit dans la r\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutique \u00e0 la fois des chances et des risques. De nombreux points ne sont pas encore clairs et demanderont un examen approfondi. La strat\u00e9gie de l\u2019UE vise \u00e0 renforcer la [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/","og_site_name":"Interpharma","article_published_time":"2023-04-26T11:54:00+00:00","article_modified_time":"2026-03-03T09:45:10+00:00","og_image":[{"width":2560,"height":1731,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse","datePublished":"2023-04-26T11:54:00+00:00","dateModified":"2026-03-03T09:45:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/"},"wordCount":601,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg","keywords":["Innovation","Communiqu\u00e9 de presse","Politique"],"inLanguage":"fr-FR","copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/","name":"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg","datePublished":"2023-04-26T11:54:00+00:00","dateModified":"2026-03-03T09:45:10+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/CH_EU_generisch-scaled.jpg","width":2560,"height":1731},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/medienmitteilung-ueberarbeitung-der-allgemeinen-eu-arzneimittelvorschriften-schwerwiegende-konsequenzen-fuer-die-schweiz-erwartet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse: R\u00e9vision de la l\u00e9gislation g\u00e9n\u00e9rale de l\u2019UE relative aux produits pharmaceutiques: cons\u00e9quences importantes attendues pour la Suisse"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12665"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12665\/revisions"}],"predecessor-version":[{"id":12666,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12665\/revisions\/12666"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/2828"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12665"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}